Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents

Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents

SARS-CoV-2 infections in children are generally asymptomatic or mild and rarely progress to severe disease and hospitalization. Why this is so remains unclear. Here we explore the potential for protection due to pre-existing cross-reactive seasonal coronavirus antibodies and compare the rate of anti...

Полное описание

Библиографические подробности
Главные авторы:	Ratcliffe, H, Tiley, K, Longet, S, Tonry, C, Roarty, C, Watson, C, Amirthalingam, G, Vichos, I, Morey, E, Douglas, NL, Marinou, S, Plested, E, Aley, PK, Galiza, E, Faust, SN, Hughes, S, Murray, C, Roderick, MR, Shackley, F, Oddie, S, Lee, TWR, Turner, DPJ, Raman, M, Owens, S, Turner, PJ, Cockerill, H, Lopez Bernal, J, Ijaz, S, Poh, J, Shute, J, Linley, E, Borrow, R, Hoschler, K, Brown, KE, Carroll, MW, Klenerman, P, Dunachie, SJ, Ramsay, M, Voysey, M, Waterfield, T, Snape, MD
Формат:	Journal article
Язык:	English
Опубликовано:	Elsevier 2023

Схожие документы

Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
по: Helen Ratcliffe, и др.
Опубликовано: (2023-12-01)

Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021
по: Ratcliffe, H, и др.
Опубликовано: (2022)

The Role of Intestinal Epithelial Permeability in Multisystem Inflammatory Syndrome in Children: A Case–Control Study
по: Cathal Roarty, и др.
Опубликовано: (2024-08-01)

PANDEMIC HUMAN CORONAVIRUS – CHARACTERIZATION AND COMPARISON OF SELECTED PROPERTIES OF HCOV-SARS AND HCOV-MERS
по: Katarzyna W. Pancer
Опубликовано: (2018-06-01)

Development of Primer Panels for Whole-Genome Amplification and Sequencing of Human Seasonal Coronaviruses: hCoV-OC43, hCoV-HKU1, hCoV-229E, and hCoV-NL63
по: Tamila Musaeva, и др.
Опубликовано: (2024-12-01)

Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study [version 2; peer review: 2 approved]
по: Robert W. Aldridge, и др.
Опубликовано: (2020-12-01)

Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43
по: Virginia Fuochi, и др.
Опубликовано: (2023-03-01)

Human Coronaviruses HCoV-NL63 and HCoV-HKU1 in Hospitalized Children with Acute Respiratory Infections in Beijing, China
по: Li-Jin Cui, и др.
Опубликовано: (2011-01-01)

Seroconversion to HCoV-NL63 in Rhesus Macaques
по: Lia van der Hoek, и др.
Опубликовано: (2009-10-01)

HCoV-NL63 and HCoV-HKU1 seroprevalence and its relationship with the clinical features of COVID-19 patients from Villavicencio, Colombia
по: Lida Carolina Lesmes-Rodríguez, и др.
Опубликовано: (2024-08-01)

Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia
по: Sean A. Lynch, и др.
Опубликовано: (2021-08-01)

The transcriptional and translational landscape of HCoV-OC43 infection.
по: Stefan Bresson, и др.
Опубликовано: (2025-01-01)

Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator
по: Yongkang Chen, и др.
Опубликовано: (2022-04-01)

Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein
по: Jiangchao Xiang, и др.
Опубликовано: (2022-11-01)

55: DEVELOPMENT OF A NOVEL IN-VITRO HCOV-OC43 SCREENING METHOD
по: S. Haynes, и др.
Опубликовано: (2022-11-01)

The human coronavirus HCoV-229E S-protein structure and receptor binding
по: Zhijie Li, и др.
Опубликовано: (2019-10-01)

Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1)
по: Martin Dugas, и др.
Опубликовано: (2021-04-01)

Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice
по: Alvaro A. Ordonez, и др.
Опубликовано: (2022-03-01)

Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex
по: Yongmei Feng, и др.
Опубликовано: (2022-12-01)

Utilizing HCoV-OC43 to better understand the neurological impact of COVID-19
по: Catherine LaCourse
Опубликовано: (2024-12-01)

HCoV‐HKU1 and TMPRSS2 interaction: uncovering mechanisms of viral invasion
по: Zehan Pang, и др.
Опубликовано: (2025-01-01)

Inhibition by components of Glycyrrhiza uralensis of 3CLpro and HCoV-OC43 proliferation
по: Jang Hoon Kim, и др.
Опубликовано: (2023-12-01)

HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients
по: Sophie Steiner, и др.
Опубликовано: (2020-12-01)

Co-circulation of Four Human Coronaviruses (HCoVs) in Queensland Children with Acute Respiratory Tract Illnesses in 2004
по: Theo P. Sloots, и др.
Опубликовано: (2012-04-01)

Corrigendum: Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex
по: Yongmei Feng, и др.
Опубликовано: (2024-12-01)

Genetic tracing of HCoV-19 for the re-emerging outbreak of COVID-19 in Beijing, China
по: Jing Yang, и др.
Опубликовано: (2020-08-01)

Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry
по: Huan Sun, и др.
Опубликовано: (2020-01-01)

Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro
по: Sébastien Pasquereau, и др.
Опубликовано: (2021-02-01)

Disinfection Effect of High-pressure Carbon Dioxide on Human Coronavirus (hCoV-229E)
по: Peng NING, и др.
Опубликовано: (2023-01-01)

A Mouse-Adapted Model of HCoV-OC43 and Its Usage to the Evaluation of Antiviral Drugs
по: Peifang Xie, и др.
Опубликовано: (2022-05-01)

Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1
по: Nehemya Friedman, и др.
Опубликовано: (2018-09-01)

IL6-mediated HCoV-host interactome regulatory network and GO/Pathway enrichment analysis.
по: Gianfranco Politano, и др.
Опубликовано: (2020-09-01)

ESCRT Protein VPS4A Is Required for the Formation of Replication Centers and Replication of Human Coronavirus 229E (HCoV-229E)
по: Rinki Kumar, и др.
Опубликовано: (2024-08-01)

Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
по: Irene A. Abela, и др.
Опубликовано: (2024-02-01)

Comparison of Selected Characteristics of SARS-CoV-2, SARS-CoV, and HCoV-NL63
по: Darina Bačenková, и др.
Опубликовано: (2021-02-01)

Comparison of SARS-CoV-2- and HCoV-Specific T Cell Response Using IFN-γ ELISpot
по: Laura Thümmler, и др.
Опубликовано: (2021-08-01)

Erythromycin Estolate Is a Potent Inhibitor Against HCoV-OC43 by Directly Inactivating the Virus Particle
по: Xiaohuan Wang, и др.
Опубликовано: (2022-07-01)

Cryo-EM analysis of the HCoV-229E spike glycoprotein reveals dynamic prefusion conformational changes
по: Xiyong Song, и др.
Опубликовано: (2021-01-01)

Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells.
по: Nehemya Friedman, и др.
Опубликовано: (2021-01-01)

Nasopharyngeal carriage of pneumococcus in children in England up to 10 years after 13-valent pneumococcal conjugate vaccine introduction: persistence of serotypes 3 and 19A and emergence of 7C
по: Tiley, KS, и др.
Опубликовано: (2022)